Girentuximab
- Generic Name
- Girentuximab
- Drug Type
- Biotech
- CAS Number
- 916138-87-9
- Unique Ingredient Identifier
- 539B57DFJF
- Background
Girentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).
- Indication
Investigated for use/treatment in gall bladder cancer and renal cell carcinoma.
Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT02883153
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath